Success Metrics

Clinical Success Rate
88.9%

Based on 16 completed trials

Completion Rate
89%(16/18)
Active Trials
5(18%)
Results Posted
50%(8 trials)
Terminated
2(7%)

Phase Distribution

Ph not_applicable
2
7%
Ph phase_4
9
32%
Ph phase_2
7
25%
Ph phase_3
7
25%
Ph phase_1
2
7%

Phase Distribution

2

Early Stage

7

Mid Stage

16

Late Stage

Phase Distribution27 total trials
Phase 1Safety & dosage
2(7.4%)
Phase 2Efficacy & side effects
7(25.9%)
Phase 3Large-scale testing
7(25.9%)
Phase 4Post-market surveillance
9(33.3%)
N/ANon-phased studies
2(7.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

16 of 18 finished

Non-Completion Rate

11.1%

2 ended early

Currently Active

5

trials recruiting

Total Trials

28

all time

Status Distribution
Active(5)
Completed(16)
Terminated(2)
Other(5)

Detailed Status

Completed16
unknown5
Recruiting4
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
28
Active
5
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (7.4%)
Phase 27 (25.9%)
Phase 37 (25.9%)
Phase 49 (33.3%)
N/A2 (7.4%)

Trials by Status

active_not_recruiting14%
recruiting414%
completed1657%
unknown518%
terminated27%

Recent Activity

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more
NCT05543642Phase 4

The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)

Active Not Recruiting
NCT05794230Phase 3

Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa

Completed
NCT06855160Phase 3

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

Recruiting
NCT06806137Phase 3

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age

Recruiting
NCT01824537Phase 4

Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study

Completed
NCT06740630Phase 3

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

Recruiting
NCT05084508Phase 2

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

Completed
NCT06693895Phase 3

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

Recruiting
NCT01926860Phase 4

PCV13 + Hepatitis a Vaccine for Adults

Completed
NCT03537508Phase 3

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Completed
NCT00139113Phase 4

Immunogenicity Study of an Inactivated Hepatitis A Vaccine in Infants and Young Children

Completed
NCT06184230Phase 4

Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination.

Unknown
NCT04515147Phase 2

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Completed
NCT02376036Phase 1

Phase 1 Study of MGD010 in Healthy Subjects

Completed
NCT00139139Not Applicable

A Study to Compare the Efficacy of Hepatitis A Vaccine and Immune Globulin When Given After Exposure to Hepatitis A

Completed
NCT02747407

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

Completed
NCT02038907Phase 2

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine

Completed
NCT03231605Phase 4

Comparative Immunogenicity Study of Two Hepatitis A Vaccines

Unknown
NCT02564237Phase 1

A Controlled Study to Evaluate the Safety and Immunogenicity of StreptAnova™ in Healthy Adults

Unknown
NCT01339000Phase 2

Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

Terminated

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
28